Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Obstetrics and Gynecology
|
April 1, 1986
Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors
Y S Fu, J Ro, J W Reagan, et al.
Journal of Biological Response Modifiers
|
August 1, 1984
Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum
A Lichtenstein, J Berek, R Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust
F Balkwill, R C Bast, J Berek, et al.
Gynecologic Oncology Reports
|
June 22, 2018
Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities
L Chuang, J Berek, T Randall, et al.
Journal for Immunotherapy of Cancer
|
June 23, 2016
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
H J Gray, B Benigno, J Berek, et al.
Gynecologic Oncology
|
December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)
F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Obstetrics and Gynecology
|
April 1, 1986
Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors
Y S Fu, J Ro, J W Reagan, et al.
Journal of Biological Response Modifiers
|
August 1, 1984
Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum
A Lichtenstein, J Berek, R Bast, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2003
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust
F Balkwill, R C Bast, J Berek, et al.
Gynecologic Oncology Reports
|
June 22, 2018
Collaborations in gynecologic oncology education and research in low- and middle- income countries: Current status, barriers and opportunities
L Chuang, J Berek, T Randall, et al.
Journal for Immunotherapy of Cancer
|
June 23, 2016
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
H J Gray, B Benigno, J Berek, et al.
Gynecologic Oncology
|
December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)
F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 26, 2017
Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors
J McGee, M Bookman, P Harter, et al.
Page
of 2